Kroger Shares Rise As Pharmacies Add Eli Lilly's Zepbound KwikPen

by

The Kroger Co. (NYSE: KR) shares are up on Friday as the company expands access to high-demand weight management medication.

The company confirmed the launch of Zepbound KwikPen at participating Kroger pharmacies. The Zepbound KwikPen is a multi-dose delivery option for Eli Lilly and Company's (NYSE: LLY) GLP-1 therapy, now available for self-pay patients.

Kroger's stock performance is moving in tandem with the overall market trends, with the consumer discretionary sector gaining 0.21% today. This aligns with

KR Technical Analysis

The stock is currently trading 7.2% above its 20-day simple moving average (SMA) and 14.5% above its 100-day SMA, demonstrating strong short-term momentum.

Over the past 12 months, shares have increased by 13.44% and are positioned closer to their 52-week highs than to their lows.

The RSI is at 66.72, which is considered neutral territory, while the MACD shows a bullish signal with a value of 1.9724, above its signal line at 1.5882. This combination suggests that while the stock is nearing overbought territory, the bullish momentum remains intact.

  • Key Resistance: $76.50
  • Key Support: $61.00
Kroger is currently underperforming its sector, with a daily gain of 0.13% compared to the Consumer Discretionary sector's increase of 0.21%. The sector ranks 8 out of 11, reflecting mid-tier performance, and has seen a decline of 5.15% over the past 30 days, indicating a challenging environment for consumer discretionary stocks.

Despite the current underperformance, Kroger's recent initiatives may help bolster its position within the sector. The company's focus on expanding access to affordable healthcare solutions aligns well with evolving consumer demands, which could provide a competitive edge moving forward.

The recent launch of Zepbound KwikPen at Kroger pharmacies highlights the company's commitment to making healthcare more accessible and affordable. This strategic move not only enhances Kroger's service offerings but also positions the company favorably in a competitive retail landscape.

Earnings & Analyst Outlook

Kroger is slated to provide its next financial update on June 22, 2026 (estimated).

  • EPS Estimate: $1.59 (Up from $1.49)
  • Revenue Estimate: $45.39 Billion (Up from $45.12 Billion)
  • Valuation: P/E of 48.7x (Indicates premium valuation)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $74.07. Recent analyst moves include:

  • Evercore ISI Group: Outperform (Raises Target to $83.00) (Mar. 9)
  • Citigroup: Neutral (Raises Target to $71.00) (Mar. 9)
  • Roth Capital: Buy (Raises Target to $78.00) (Mar. 6)
Top ETF Exposure

  • Freedom 100 Emerging Markets ETF (NYSE: FRDM): 7.93% Weight
  • Invesco AI and Next Gen Software ETF (NYSE: IGPT): 9.40% Weight
  • Macquarie Focused Emerging Markets Equity ETF (NASDAQ: EMEQ): 9.87% Weight
Significance: Because KR carries such a heavy weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

KR Stock Price Activity: Kroger shares were up 0.17% at $75.09 at the time of publication on Friday, according to Benzinga Pro data.